Common Links in Swine Flu Deaths...

http://articles.mercola.com/sites/articles/archive/2009/10/31/CDC-Says-Kids-T...


A recent study by the Centers for Disease Control and Prevention (CDC) found that of the 36 children who died from H1N1 from April to August, six had no chronic health conditions. But all of them had a co-occurring bacterial infection.The most common co-occurring infection that causes flu-related deaths is staphylococcus aureus. A third of the population carries it, most in their nose or on their skin. The flu causes upper respiratory damage, which allows the staph to make its way into the lungs.

60-Minutes’ Story Also Highlighted Bacterial Infection as Flu Tragedy

Their segment, which aired last Sunday, did ask some hard questions to the Assistant Surgeon General. But they didn't ask why CDC officials persist in telling the public that this H1N1 strain of influenza is quite dangerous when the experience of those in the southern hemisphere (which just finished their flu season) is in direct conflict with what the CDC is telling the American people.

- - - - - - - - - - - - - - - - - - - - - - - -

The researchers also found that although fewer infants developed a fever after getting acetaminophen, they also developed significantly fewer antibodies against the disease they were vaccinated against. They believe the acetaminophen’s anti-inflammatory activity might interfere with your body’s immune system antibody response, which could explain why the vaccine was rendered less effective.

However, what is not mentioned by either MSN, or foodconsumer.org, who also ran an article on these findings, is that a lowered immune response also means you're more susceptible to develop other infections. And, as we now know, it is secondary infections such as bacterial staph infections that turn out to be deadly -- not the flu virus in and of itself.

================================================

Proof that European H1N1 Vaccines Contain Mercury, Squalene and TWEEN 80

Regarding the first quote, if “no harmful effects have been reported from thimerosal at doses used in vaccines” then, while reading the next sentence, why promote the push to eliminate it from vaccines? The quote of and by itself by its mere formulation is oxymoronic and therefore suspicion raising.

Here’s a Material Safety Data Sheet of thimerosal:

is toxic, alters genetic material,

Effects of Overexposure: Topical allergic dermatitis has been reported. Thimerosal contains mercury. Mercury poisoning may occur and topical hypersensitivity reactions may be seen. Early signs of mercury poisoning in adults are nervous system effects, including narrowing of the visual field and numbness in the extremities. Exposure to mercury in utero and in children may cause mild to severe mental retardation and mild to severe motor coordination impairment.

Here is a portion of the abstract of a new peer-reviewed scientific study investigating thimerosal neurotoxicity. It states quite clearly that thimerosal induces autism-like neurotoxicity:

Thimerosal-induced cellular damage as evidenced by concentration- and time-dependent mitochondrial damage, reduced oxidative-reduction activity, cellular degeneration, and cell death in the in vitro human neuronal and fetal model systems studied. Thimerosal at low nanomolar (nM) concentrations induced significant cellular toxicity in human neuronal and fetal cells. Thimerosal-induced cytoxicity is similar to that observed in AD pathophysiologic studies. Thimerosal was found to be significantly more toxic than the other metal compounds examined.informaworld.com

So the practical difference between an in vitro experiment and an in vivo experiment in this case is the blood-brain barrier (BBB), which if working to satisfaction should be able to obstruct thimerosal present in the blood from reaching the brain and so prevent it from doing damage.

This assumption however is obviously unjustified if and when the BBB is not working properly and as such is incapable of blocking mercury from entering the brain. So when is the BBB compromised? For one, the BBB is not fully functional in infants.

============================================

Package insert:

http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts...


Influenza A (H1N1) 2009 Monovalent Vaccine
Manufactured by Sanofi Pasteur Inc.
Suspension for Intramuscular Injection

------------------------ADVERSE REACTIONS--------------

Adverse reaction information is based on studies conducted with seasonal trivalent Influenza Virus Vaccine.

Safety and effectiveness of Influenza A (H1N1) 2009 Monovalent Vaccine have not been established in pregnant women or nursing mothers or children <6 months of age.

Multi-dose vial, 5 mL, for 6 months of age and older, contains thimerosal, a mercury 13 derivative, added as a preservative. Each 0.5 mL dose contains 25 micrograms (mcg) mercury.

Do not administer Influenza A (H1N1) 2009 Monovalent Vaccine to anyone with a known severe hypersensitivity to egg proteins [Do they even ask this question???]

Recurrence of Guillain-Barré syndrome (GBS) has been temporally associated with the administration of influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Adverse event information from clinical trials provides the basis for identifying adverse events that appear to be related to vaccine use and for approximating the rates of these events. However, because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trial of another vaccine, and may not reflect the rates observed in practice.

Fever, malaise, myalgia, and other systemic symptoms can occur following vaccination and most often affect persons who have had no prior exposure to the influenza virus antigens in the vaccine (e.g., young children). These reactions begin 6–12 hours after vaccination and can persist for 1–2 days. [And are they giving them Tylenol???]

The following additional events have been reported during post-approval use of Fluzone vaccine. [Note it says FLUZONE.. That is because there is no study for this particular vaccine... It is ASSUMED to be the same....] Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.

Blood and Lymphatic System Disorders: Thrombocytopenia, lymphadenopathy

Immune System Disorders: Anaphylaxis, other allergic/hypersensitivity reactions (including urticaria, angioedema)

Nervous System Disorders: GBS, convulsions, myelitis (including encephalomyelitis and transverse myelitis), facial palsy (Bell’s palsy), optic neuritis/neuropathy, brachial neuritis, syncope (shortly after vaccination), dizziness, paresthesia

Vascular Disorders: Vasculitis, vasodilation/flushing

Respiratory, Thoracic and Mediastinal Disorders: Dyspnea, pharyngitis, rhinitis

Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome

General Disorders and Administration Site Conditions: Fever, pain, pruritis, asthenia/fatigue, pain in extremities, chest pain

Other Adverse Events Associated with Influenza Vaccines

Anaphylaxis has been reported after administration of influenza vaccines. Although Influenza A (H1N1) 2009 Monovalent Vaccine contains only a limited quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy. Allergic reactions include hives, angioedema, allergic asthma, and systemic anaphylaxis. [See Contraindications (4)]

The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré syndrome (GBS). Evidence for a causal relation of GBS with subsequent vaccines prepared from other influenza viruses is unclear. If influenza vaccine does pose a risk, it is probably slightly more than 1 additional case/1 million persons vaccinated.

Neurological disorders temporally associated with influenza vaccination such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy have been reported.

Microscopic polyangitis (vasculitis) has been reported temporally associated with influenza vaccination.

1. Pregnancy
Pregnancy Category C: Animal reproduction studies have not been conducted with Influenza A (H1N1) 2009 Monovalent Vaccine or Fluzone vaccine. It is also not known whether these vaccines can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Influenza A (H1N1) 2009 Monovalent Vaccine should be given to a pregnant woman only if clearly needed.

8.3. Nursing Mothers

It is not known whether Influenza A (H1N1) 2009 Monovalent Vaccine or Fluzone vaccine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this vaccine is administered to a nursing woman.

8.4. Pediatric Use

Safety and effectiveness in pediatric subjects below the age of 6 months have not been established. [In utero is definitely <6 months....]

Geriatric Use

Page 10 of 19 sanofi pasteur 10 September 2009_v0.3 449/454 Influenza A (H1N1) 2009 Monovalent Vaccine LE5860-5862 Confidential/Proprietary Information

Immune response to Fluzone vaccine in subjects older than 61 years of age were lower when compared to immune responses in adults 19-59 years of age.

Gelatin 0.05% is added as a stabilizer. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 100 mcg), polyethylene glycol p-isooctylphenyl ether (not more than 0.02%),

In some human studies, antibody titer of ≥1:40 have been associated with protection from influenza illness in up to 50% of subjects.

Antibodies against one influenza virus type or subtype confer limited or no protection against another. Furthermore, antibodies to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Neither Fluzone vaccine nor Influenza A (H1N1) 2009 Monovalent Vaccine have been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility.